GILDGilead SciencesRunning, no new patients
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 603 (final count)
- Started
- Nov 17, 2021
- Main results expected
- Nov 29, 2023
- Fully finished
- Jan 2027
- Results posted
- Jan 14, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to 24.4 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05089734 · record last updated 2026-05-07 · checked 2026-11-09 15:47 UTC